MondoA Inhibitors
MondoA Inhibitors primarily comprises chemicals that indirectly influence MondoA activity by modulating metabolic pathways and transcriptional regulation. MondoA, being a transcription factor involved in metabolic control, does not have direct chemical inhibitors, but its function can be indirectly affected by compounds that alter cellular metabolism and energy homeostasis. For instance, Metformin and Phenformin exert their effects primarily by activating AMPK, a critical regulator of cellular energy status. This activation can lead to alterations in metabolic pathways that MondoA is known to regulate, such as glucose and lipid metabolism.
Resveratrol, a natural polyphenol, is known for its potential effects on sirtuins and AMPK, impacting pathways associated with longevity and metabolic diseases. SRT1720, specifically targeting SIRT1, can influence gene expression patterns related to metabolism, which may indirectly affect MondoA's regulatory role. PPAR agonists, such as Rosiglitazone and Pioglitazone, demonstrate another indirect approach. By modulating lipid metabolism and glucose homeostasis, these compounds can alter the metabolic state of cells, potentially influencing the transcriptional activity of MondoA.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin can influence cellular metabolism, potentially affecting MondoA's activity indirectly. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
As a PPARγ agonist, Rosiglitazone modulates lipid metabolism and glucose homeostasis, which could have downstream effects on MondoA-regulated pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, impacts cellular growth and metabolism, possibly influencing MondoA activity by altering metabolic states. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
This glucose analog inhibits glycolysis and can indirectly affect MondoA's activity, as MondoA is involved in metabolic regulation. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
As a PPARα agonist, WY-14643 affects lipid metabolism, potentially influencing pathways regulated by MondoA. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $92.00 | 1 | |
Berberine has multiple effects on metabolism and could indirectly impact MondoA's activity through its role in regulating metabolic pathways. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMPK, influencing metabolic pathways and potentially having an indirect effect on MondoA's function. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid, a metabolite of vitamin A, regulates gene expression and might affect MondoA indirectly through its impact on cellular metabolism. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Another PPARγ agonist, Pioglitazone affects glucose and lipid metabolism, potentially influencing MondoA's metabolic regulatory roles. | ||||||
SRT1720 | 1001645-58-4 | sc-364624 sc-364624A | 5 mg 10 mg | $197.00 $364.00 | 13 | |
SRT1720 is an activator of SIRT1, a protein involved in metabolic regulation, which could indirectly influence MondoA's activity. | ||||||